Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07047014 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke

Study acronym: ARTS-MeVO
StatusRecruiting
PhasePhase 3
Started2025-07-30
View on ClinicalTrials.gov ↗

Amendment history

2026-03-27
Study Status, Study Description, Arms and Interventions, Eligibility v4
Eligibility criteria+209 characters
[...] onsible for the signs and symptoms of acute ischemic stroke; (4)Neuroimaging criteria: a) Perfusion criteria:Target mismatch profile on CT perfusion or MRI+MR perfusion (4ischemic core volume <70mL, mismatch ratio >1.2, mismatch volume >10mL); b) If neither MRI or CT perfusion is available at the site : an Alberta Stroke Program Early CT Score [ASPECTS] of 8 or more on NCCT /MRI-DWI or PC-ASPECTS of 8 or more on NCCT/MRI-DWI. (5)Pre-stroke modified Rankin scale (mRS) score ≤1; (56)Baseline National Institutes of Health Stroke Scale (NIHSS) ≥6 or NIHSS 3-5 with disabling symptoms; (6)Neuroimagi [...] [...]
Study description+122 characters
[...] e volume <70mL, mismatch ratio>1.2, mismatch volume >10mL). If neither MRI or CT perfusion is available at the site, an ASPECTS/PC-ASPECTS of 8 or more on NCCT /MRI-DWI will be used.We will randomly assign eligible patients to receive tenecte [...]
2025-11-17
Study Status v3
Re-verified, no change to tracked fields
2025-08-01
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Study sites2→7
2025-07-03
Study Status, Sponsor/Collaborators, Contacts/Locations v1
Collaborators1 to 2 entries
Chinese Stroke Association
2025-06-24
Original filing
Beijing Tiantan Hospital
280 trials monitored
See 4 trials at risk
Stroke
3,268 trials monitored
See 122 trials at risk
Results from recent several trials provided data showing limits to the effectiveness of thrombectomy for ischemic stroke due to medium vessel occlusions.The benefit-risk profile of thrombolysis for these patients has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of tenecteplase (0.25mg/kg, maximum dose 25mg) compared to standard medical care for patients with acute ischemic stroke due to medium vessel occlusion (MeVO) within 4.5 to 24 hours from symptom onset.
Trial Details
NCT Number NCT07047014
Lead Sponsor Beijing Tiantan Hospital
Collaborators: First Affiliated Hospital of Zhejiang University, Chinese Stroke Association
Conditions Stroke, Ischemic, Medium Vessel Occlusions
Enrollment 596 participants
Start Date 2025-07-30
Primary Completion 2027-03-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-01